Table 3.
Clinical Outcomes in the First Year after Allo-HCT for Patients with or without Virus-Associated HC, Stratified by the Presence or Absence of GVHD
| Characteristic | Patients with Virus-Associated HC (n = 759) | Patients without Virus-Associated HC (n = 12,604) | P Value |
|---|---|---|---|
| Allo-HCT patients with GVHD, n (%) | 621 (81.8) | 8278 (65.7) | <.0001 |
| All-cause mortality | 144 (23.2) | 1527 (18.4) | .0035 |
| Renal impairment during follow-up | 360 (58.0) | 3129 (37.8) | <.0001 |
| Renal impairment during baseline | 128 (20.6) | 1782 (21.5) | .5922 |
| Renal impairment during follow-up and not during baseline | 268 (43.2) | 1997 (24.1) | <.0001 |
| Urinary retention during follow-up | 33 (5.3) | 177 (2.1) | <.0001 |
| Allo-HCT patients without GVHD, n (%) | 138 (18.2) | 4326 (34.3) | <.0001 |
| All-cause mortality | 33 (23.9) | 887 (20.5) | .3297 |
| Renal impairment during follow-up | 78 (56.5) | 1150 (26.6) | <.0001 |
| Renal impairment during baseline | 37 (26.8) | 916 (21.2) | .1116 |
| Renal impairment during follow-up and not during baseline | 50 (36.2) | 682 (15.8) | <.0001 |
| Urinary retention during follow-up | * | 48 (1.1) | — |
Renal impairment was defined through ICD-9 and ICD-10 diagnosis codes for glomerular diseases, renal tubulo-interstitial diseases, acute kidney failure and chronic kidney disease, urolithiasis, other disorders of the kidney and the ureter, kidney injury, and dialysis.
*
Cells with ≤5 observations are not reported.